The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
The role of lipid components in lipid nanoparticles for vaccines and gene therapy
Open accessAbstract
Graphical abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“The tremendous success of the vaccines from Pfizer-BioNTech (BNT162b2, also known as Comirnaty ) [1] and Moderna (mRNA1273, also known as Spikevax ) [2] in combatting COVID-19 has demonstrated the value and rapid translational potential of lipid nanoparticles (LNPs).”
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · cited 1×
“The tremendous success of the vaccines from Pfizer-BioNTech (BNT162b2, also known as Comirnaty ) [1] and Moderna (mRNA1273, also known as Spikevax ) [2] in combatting COVID-19 has demonstrated the value and rapid translational potential of lipid nanoparticles (LNPs).”
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“One example is liposomal doxorubicin, also called Doxil , the first FDA-approved nanomedicine [16], which contains hydrogenated soy phosphatidylcholine (mainly DSPC), cholesterol, and PEG-lipid at a 56:38:5 molar ratio [17]).”
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 1×
“Many informative reviews about employing LNPs for vaccines and gene therapy [8,9] have largely focused on how nucleic acid cargo elicits biological changes and enacts therapeutic effects, with less attention to the LNP.”
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Biomolecular coronas provide the biological identity of nanosized materials
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.207 · Cited by 3,017
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Self-citationPharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Pharmacokinetics and Biodistribution of Nanoparticles
Li, S.-D., & Huang, L. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800049w · Cited by 1,568
mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
Self-citationGabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Mechanism of hard-nanomaterial clearance by the liver
Tsoi, K. M., MacParland, S. A., Ma, X.-Z., Spetzler, V. N., Echeverri, J., Ouyang, B., Fadel, S. M., Sykes, E. A., Goldaracena, N., Kaths, J. M., et al. (2016) · Nature Materials · doi:10.1038/nmat4718 · Cited by 1,010
Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling
Sahay, G., Querbes, W., Alabi, C., Eltoukhy, A., Sarkar, S., Zurenko, C., Karagiannis, E., Love, K., Chen, D., Zoncu, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2614 · Cited by 948
Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines
Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.013 · Cited by 927
Intermolecular and Surface Forces
(2011) · doi:10.1016/c2009-0-21560-1 · Cited by 871
Nanoprobes with near-infrared persistent luminescence for in vivo imaging
le Masne de Chermont, Q., Chanéac, C., Seguin, J., Pellé, F., Maîtrejean, S., Jolivet, J.-P., Gourier, D., Bessodes, M., & Scherman, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702427104 · Cited by 834
Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820 · cited 1×
“Interestingly, while MC3 is not completely biodegradable and metabolites persist in rats and non-human primates [48], the doses required for clinical application show no evidence of toxicity [3].”
Kauffman, K. J., Dorkin, J. R., Yang, J. H., Heartlein, M. W., DeRosa, F., Mir, F. F., Fenton, O. S., & Anderson, D. G. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b02497 · Cited by 796
Alameh, M.-G., Tombácz, I., Bettini, E., Lederer, K., Ndeupen, S., Sittplangkoon, C., Wilmore, J. R., Gaudette, B. T., Soliman, O. Y., Pine, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.001 · Cited by 775
The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery
Cheng, X., & Lee, R. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.022 · Cited by 703
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA
Belliveau, N. M., Huft, J., Lin, P. J., Chen, S., Leung, A. K., Leaver, T. J., Wild, A. W., Lee, J. B., Taylor, R. J., Tam, Y. K., et al. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.28 · Cited by 685 · cited 1×
“Multiple studies have shown that increasing the molar ratio of the PEG-lipid coheres with significantly smaller LNPs, independent of other lipid components [24,52,64].”
Kulkarni, J. A., Darjuan, M. M., Mercer, J. E., Chen, S., van der Meel, R., Thewalt, J. L., Tam, Y. Y. C., & Cullis, P. R. (2018) · ACS Nano · doi:10.1021/acsnano.8b01516 · Cited by 663
Munro, A. P. S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02717-3 · Cited by 642
Maier, M. A., Jayaraman, M., Matsuda, S., Liu, J., Barros, S., Querbes, W., Tam, Y. K., Ansell, S. M., Kumar, V., Qin, J., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.124 · Cited by 625
Safra, T., Muggia, F., Jeffers, S., Tsao-Wei, D. D., Groshen, S., Lyass, O., Henderson, R., Berry, G., & Gabizon, A. (2000) · Annals of Oncology · doi:10.1023/a:1008365716693 · Cited by 618
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity
Whitehead, K. A., Dorkin, J. R., Vegas, A. J., Chang, P. H., Veiseh, O., Matthews, J., Fenton, O. S., Zhang, Y., Olejnik, K. T., Yesilyurt, V., et al. (2014) · Nature Communications · doi:10.1038/ncomms5277 · Cited by 615
Dams, E. T. M., Laverman, P., Oyen, W. J. G., Storm, G., Scherphof, G. L., van der Meer, J. W. M., Corstens, F. H. M., & Boerman, O. C. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35391-1 · Cited by 607
On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids
Hafez, I., Maurer, N., & Cullis, P. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301506 · Cited by 601
Lipid nanoparticles enabling gene therapies: from concepts to clinical utility
Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0721 · Cited by 592
Self-citationCationic lipid saturation influences intracellular delivery of encapsulated nucleic acids
Heyes, J., Palmer, L., Bremner, K., & MacLachlan, I. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.014 · Cited by 572
Shi, D., Beasock, D., Fessler, A., Szebeni, J., Ljubimova, J. Y., Afonin, K. A., & Dobrovolskaia, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114079 · Cited by 535
Yanez Arteta, M., Kjellman, T., Bartesaghi, S., Wallin, S., Wu, X., Kvist, A. J., Dabkowska, A., Székely, N., Radulescu, A., Bergenholtz, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720542115 · Cited by 534
Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics
Kulkarni, J. A., Witzigmann, D., Chen, S., Cullis, P. R., & van der Meel, R. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00368 · Cited by 527
Self-citationPEGylated liposomes: immunological responses
Mohamed, M., Abu Lila, A. S., Shimizu, T., Alaaeldin, E., Hussein, A., Sarhan, H. A., Szebeni, J., & Ishida, T. (2019) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2019.1627174 · Cited by 523
The dose threshold for nanoparticle tumour delivery
Ouyang, B., Poon, W., Zhang, Y.-N., Lin, Z. P., Kingston, B. R., Tavares, A. J., Zhang, Y., Chen, J., Valic, M. S., Syed, A. M., et al. (2020) · Nature Materials · doi:10.1038/s41563-020-0755-z · Cited by 514
Mui, B. L., Tam, Y. K., Jayaraman, M., Ansell, S. M., Du, X., Tam, Y. Y. C., Lin, P. J., Chen, S., Narayanannair, J. K., Rajeev, K. G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.66 · Cited by 505
Hepatic uptake of chylomicron remnants
Cooper, A. D. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34932-4 · Cited by 499
Hatakeyama, H., Akita, H., & Harashima, H. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00059 · Cited by 495
Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs
Lokugamage, M. P., Vanover, D., Beyersdorf, J., Hatit, M. Z. C., Rotolo, L., Echeverri, E. S., Peck, H. E., Ni, H., Yoon, J.-K., Kim, Y., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00786-x · Cited by 495
Semple, S. C., Klimuk, S. K., Harasym, T. O., Dos Santos, N., Ansell, S. M., Wong, K. F., Maurer, N., Stark, H., Cullis, P. R., Hope, M. J., et al. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(00)00343-6 · Cited by 454
Munro, A., Janani, L., Cornelius, V. R., Aley, P. K., Babbage, G., Baxter, D. N., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., et al. (2021) · Sussex Research Online (University of Sussex) · doi:10.1016/s0140-6736%2821%2902717-3 · Cited by 432
Carrasco, M. J., Alishetty, S., Alameh, M.-G., Said, H., Wright, L., Paige, M., Soliman, O., Weissman, D., Cleveland, T. E., Grishaev, A., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02441-2 · Cited by 428
Sebastiani, F., Yanez Arteta, M., Lerche, M., Porcar, L., Lang, C., Bragg, R. A., Elmore, C. S., Krishnamurthy, V. R., Russell, R. A., Darwish, T., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c10064 · Cited by 409
On the role of helper lipids in lipid nanoparticle formulations of siRNA
Kulkarni, J. A., Witzigmann, D., Leung, J., Tam, Y. Y. C., & Cullis, P. R. (2019) · Nanoscale · doi:10.1039/c9nr09347h · Cited by 402
Self-citationKim, M., Jeong, M., Hur, S., Cho, Y., Park, J., Jung, H., Seo, Y., Woo, H. A., Nam, K. T., Lee, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf4398 · Cited by 385
Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery
Eygeris, Y., Patel, S., Jozic, A., & Sahay, G. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c01386 · Cited by 379
Impact of lipid nanoparticle size on mRNA vaccine immunogenicity
Hassett, K. J., Higgins, J., Woods, A., Levy, B., Xia, Y., Hsiao, C. J., Acosta, E., Almarsson, Ö., Moore, M. J., & Brito, L. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.021 · Cited by 367
Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA
Chen, S., Tam, Y. Y. C., Lin, P. J. C., Sung, M. M. H., Tam, Y. K., & Cullis, P. R. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.059 · Cited by 366
Leung, A. K. K., Hafez, I. M., Baoukina, S., Belliveau, N. M., Zhigaltsev, I. V., Afshinmanesh, E., Tieleman, D. P., Hansen, C. L., Hope, M. J., & Cullis, P. R. (2012) · The Journal of Physical Chemistry C · doi:10.1021/jp303267y · Cited by 360
Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems
Leung, A. K. K., Tam, Y. Y. C., Chen, S., Hafez, I. M., & Cullis, P. R. (2015) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b02891 · Cited by 359
Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics
Dahlman, J. E., Kauffman, K. J., Xing, Y., Shaw, T. E., Mir, F. F., Dlott, C. C., Langer, R., Anderson, D. G., & Wang, E. T. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620874114 · Cited by 335
Johnsen, K. B., Gudbergsson, J. M., Andresen, T. L., & Simonsen, J. B. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.11.006 · Cited by 317
Self-citationStabilized plasmid-lipid particles: construction and characterization
Wheeler, J. J., Palmer, L., Ossanlou, M., MacLachlan, I., Graham, R. W., Zhang, Y. P., Hope, M. J., Scherrer, P., & Cullis, P. R. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300821 · Cited by 299
The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy
Francia, V., Schiffelers, R. M., Cullis, P. R., & Witzigmann, D. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00366 · Cited by 299
Self-citationLipid Polymorphism:The Molecular Basis of Nonbilayer Phases
Gruner, S. M., Cullis, P. R., Hope, M. J., & Tilcock, C. P. S. (1985) · Annual Review of Biophysics and Biophysical Chemistry · doi:10.1146/annurev.bb.14.060185.001235 · Cited by 296
Tombácz, I., Laczkó, D., Shahnawaz, H., Muramatsu, H., Natesan, A., Yadegari, A., Papp, T. E., Alameh, M.-G., Shuvaev, V., Mui, B. L., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.004 · Cited by 296
Influence of Cholesterol on the Association of Plasma Proteins with Liposomes
Semple, S. C., Chonn, A., & Cullis, P. R. (1996) · Biochemistry · doi:10.1021/bi950414i · Cited by 291
Ishida, T., Atobe, K., Wang, X., & Kiwada, H. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.08.017 · Cited by 287
Judge, A., McClintock, K., Phelps, J. R., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.014 · Cited by 280
The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA
Patel, P., Ibrahim, N. M., & Cheng, K. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.03.002 · Cited by 280
The Structural Role of Cholesterol in Cell Membranes: From Condensed Bilayers to Lipid Rafts
Krause, M. R., & Regen, S. L. (2014) · Accounts of Chemical Research · doi:10.1021/ar500260t · Cited by 269
Functional groups on polystyrene model nanoparticles: Influence on protein adsorption
Gessner, A., Lieske, A., Paulke, B., & Müller, R. H. (2003) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.10371 · Cited by 239
Encapsulation state of messenger RNA inside lipid nanoparticles
Brader, M. L., Williams, S. J., Banks, J. M., Hui, W. H., Zhou, Z. H., & Jin, L. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.03.012 · Cited by 236 · cited 2×
“Recent studies have investigated LNP structure/lipid arrangement by using cryo-TEM [94,99,100], molecular dynamics (MD) [101], small-angle neutron scattering (SANS) [54], small-angle x-ray scattering (SAXS) [54,94], fluorescence microscopy [102], and NMR methods [103].”
Maurer, N., Wong, K. F., Stark, H., Louie, L., McIntosh, D., Wong, T., Scherrer, P., Semple, S. C., & Cullis, P. R. (2001) · Biophysical Journal · doi:10.1016/s0006-3495(01)76202-9 · Cited by 232
Song, L. Y., Ahkong, Q. F., Rong, Q., Wang, Z., Ansell, S., Hope, M. J., & Mui, B. (2002) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00399-6 · Cited by 228
Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA
Kulkarni, J. A., Myhre, J. L., Chen, S., Tam, Y. Y. C., Danescu, A., Richman, J. M., & Cullis, P. R. (2017) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.12.014 · Cited by 225
Self-citationSuzuki, T., Suzuki, Y., Hihara, T., Kubara, K., Kondo, K., Hyodo, K., Yamazaki, K., Ishida, T., & Ishihara, H. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119792 · Cited by 225
Holland, J. W., Hui, C., Cullis, P. R., & Madden, T. D. (1996) · Biochemistry · doi:10.1021/bi952000v · Cited by 223
Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale
Paramasivam, P., Franke, C., Stöter, M., Höijer, A., Bartesaghi, S., Sabirsh, A., Lindfors, L., Arteta, M. Y., Dahlén, A., Bak, A., et al. (2022) · Journal of Cell Biology · doi:10.1083/jcb.202110137 · Cited by 223
Zhang, X., Goel, V., & Robbie, G. J. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1553 · Cited by 213
Semple, S. C., Harasym, T. O., Clow, K. A., Ansell, S. M., Klimuk, S. K., & Hope, M. J. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078113 · Cited by 211
Viger-Gravel, J., Schantz, A., Pinon, A. C., Rossini, A. J., Schantz, S., & Emsley, L. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b10795 · Cited by 202 · cited 3×
“Recent studies have investigated LNP structure/lipid arrangement by using cryo-TEM [94,99,100], molecular dynamics (MD) [101], small-angle neutron scattering (SANS) [54], small-angle x-ray scattering (SAXS) [54,94], fluorescence microscopy [102], and NMR methods [103].”
Alcoholic liver injury: Defenestration in noncirrhotic livers—a scanning electron microscopic study
Horn, T., Christoffersen, P., & Henriksen, J. H. (1987) · Hepatology · doi:10.1002/hep.1840070117 · Cited by 182
Correlation of the cytotoxic effects of cationic lipids with their headgroups
Cui, S., Wang, Y., Gong, Y., Lin, X., Zhao, Y., Zhi, D., Zhou, Q., & Zhang, S. (2018) · Toxicology Research · doi:10.1039/c8tx00005k · Cited by 179
Seynhaeve, A. L. B., Dicheva, B. M., Hoving, S., Koning, G. A., & ten Hagen, T. L. M. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.034 · Cited by 177
Aerosolizable Lipid Nanoparticles for Pulmonary Delivery of mRNA through Design of Experiments
Zhang, H., Leal, J., Soto, M. R., Smyth, H. D. C., & Ghosh, D. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111042 · Cited by 165
Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics
Dammes, N., Goldsmith, M., Ramishetti, S., Dearling, J. L. J., Veiga, N., Packard, A. B., & Peer, D. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00928-x · Cited by 159
Stabilized plasmid-lipid particles for systemic gene therapy
Tam, P., Monck, M. A., Lee, D., Ludkovski, O., Leng, E. C., Clow, K. A., Stark, H., Scherrer, P., Graham, R. W., & Cullis, P. R. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301308 · Cited by 150
Bryantsev, V. S., Diallo, M. S., & Goddard, W. A. (2007) · The Journal of Physical Chemistry A · doi:10.1021/jp071040t · Cited by 146
Membrane Fusion with Cationic Liposomes: Effects of Target Membrane Lipid Composition
Bailey, A. L., & Cullis, P. R. (1997) · Biochemistry · doi:10.1021/bi961173x · Cited by 142
The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse
Yan, X., Kuipers, F., Havekes, L. M., Havinga, R., Dontje, B., Poelstra, K., Scherphof, G. L., & Kamps, J. A. A. M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.12.137 · Cited by 138
Zhang, X., Goel, V., Attarwala, H. Z., Sweetser, M. T., Clausen, V. A., & Robbie, G. J. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1480 · Cited by 135
Besin, G., Milton, J., Sabnis, S., Howell, R. D., Mihai, C., Burke, K. E., Benenato, K. E., Stanton, M., Smith, P., Senn, J. J., et al. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1900029 · Cited by 111
Lin, P. J. C., Tam, Y. Y. C., Hafez, I. M., Sandhu, A. P., Chen, S., Ciufolini, M. A., Nabi, I. R., & Cullis, P. R. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.05.019 · Cited by 101
A Nanoprimer To Improve the Systemic Delivery of siRNA and mRNA
Saunders, N., Paolini, M. S., Fenton, O. S., Poul, L., Devallière, J., Mpambani, F., Darmon, A., Bergère, M., Jibault, O., Germain, M., et al. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c00752 · Cited by 100
Zhang, J., Fan, H., Levorse, D. A., & Crocker, L. S. (2011) · Langmuir · doi:10.1021/la104590k · Cited by 96
Lee, J. B., Zhang, K., Tam, Y. Y. C., Tam, Y. K., Belliveau, N. M., Sung, V. Y. C., Lin, P. J. C., LeBlanc, E., Ciufolini, M. A., Rennie, P. S., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27361 · Cited by 92
Ionizable amino lipid interactions with POPC: implications for lipid nanoparticle function
Ramezanpour, M., Schmidt, M. L., Bodnariuc, I., Kulkarni, J. A., Leung, S. S. W., Cullis, P. R., Thewalt, J. L., & Tieleman, D. P. (2019) · Nanoscale · doi:10.1039/c9nr02297j · Cited by 88
Self-citationMünter, R., Kristensen, K., Pedersbæk, D., Larsen, J. B., Simonsen, J. B., & Andresen, T. L. (2018) · Nanoscale · doi:10.1039/c8nr07755j · Cited by 84
Self-citationTherapeutic Potential of LNP-Mediated Delivery of miR-634 for Cancer Therapy
Gokita, K., Inoue, J., Ishihara, H., Kojima, K., & Inazawa, J. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.10.045 · Cited by 84
Yamamoto, Y., Lin, P. J. C., Beraldi, E., Zhang, F., Kawai, Y., Leong, J., Katsumi, H., Fazli, L., Fraser, R., Cullis, P. R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0866 · Cited by 79
Lipid nanoparticles for mRNA delivery
Tanaka, H., Sakurai, Y., & Akita, H. (2022) · Drug Delivery System · doi:10.2745/dds.37.237 · Cited by 74
Kamanzi, A., Gu, Y., Tahvildari, R., Friedenberger, Z., Zhu, X., Berti, R., Kurylowicz, M., Witzigmann, D., Kulkarni, J. A., Leung, J., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c04862 · Cited by 69
Self-citationChallenging paradigms in tumour drug delivery
(2020) · Nature Materials · doi:10.1038/s41563-020-0676-x · Cited by 68
Khatri, N., Baradia, D., Vhora, I., Rathi, M. N., & Misra, A. R. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0193-9 · Cited by 63
Lee, J. B., Zhang, K., Tam, Y. Y. C., Quick, J., Tam, Y. K., Lin, P. J. C., Chen, S., Liu, Y., Nair, J. K., Zlatev, I., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.43 · Cited by 61
Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity
Mima, Y., Lila, A. S. A., Shimizu, T., Ukawa, M., Ando, H., Kurata, Y., & Ishida, T. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.040 · Cited by 61
Pay Attention to Biological Nanoparticles when Studying the Protein Corona on Nanomedicines
Simonsen, J. B., & Münter, R. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004611 · Cited by 55
Self-citationCationic Nanoparticle-Based Cancer Vaccines
Heuts, J., Jiskoot, W., OSSENDORP, F. A., & van der Maaden, K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050596 · Cited by 48
The influence of size and composition on the cholesterol mobilizing properties of liposomes in vivo
Rodrigueza, W. V., Pritchard, P. H., & Hope, M. J. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90270-a · Cited by 46
Delivery of Oligonucleotides Using a Self-Degradable Lipid-Like Material
Tanaka, H., Takata, N., Sakurai, Y., Yoshida, T., Inoué, T., Tamagawa, S., Nakai, Y., Tange, K., Yoshioka, H., Maeki, M., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040544 · Cited by 44
Acidic pH-induced changes in lipid nanoparticle membrane packing
Koitabashi, K., Nagumo, H., Nakao, M., Machida, T., Yoshida, K., & Sakai‐Kato, K. (2021) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2021.183627 · Cited by 41
Enhanced target cell specificity and uptake of lipid nanoparticles using RNA aptamers and peptides
Ray, R. M., Hansen, A. H., Taskova, M., Jandl, B., Hansen, J. T., Soemardy, C., Morris, K. V., & Astakhova, K. (2021) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.17.75 · Cited by 41
Protective Effect of Edaravone against Cationic Lipid-Mediated Oxidative Stress and Apoptosis
Terada, T., Kulkarni, J. A., Huynh, A., Tam, Y. Y. C., & Cullis, P. R. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00679 · Cited by 39
Self-citationMünter, R., Stavnsbjerg, C., Christensen, E., Thomsen, M. E., Stensballe, A., Hansen, A. E., Parhamifar, L., Kristensen, K., Simonsen, J. B., Larsen, J. B., et al. (2022) · Small · doi:10.1002/smll.202106529 · Cited by 35
Self-citationPizzuto, M., Gangloff, M., Scherman, D., Gay, N. J., Escriou, V., Ruysschaert, J., & Lonez, C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.029 · Cited by 26
Pedersbæk, D., Kræmer, M. K., Kempen, P. J., Ashley, J. A., Braesch‐Andersen, S., Andresen, T. L., & Simonsen, J. B. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00552 · Cited by 26
Self-citationKurimoto, S., Yoshinaga, N., Igarashi, K., Matsumoto, Y., Cabral, H., & Uchida, S. (2019) · Molecules · doi:10.3390/molecules24071303 · Cited by 24
COVID-19 vaccines poised for launch, but impact on pandemic unclear
Dolgin, E. (2020) · Nature Biotechnology · doi:10.1038/d41587-020-00022-y · Cited by 24
Harvie (2000) · doi:10.1002/(sici)1520-6017(200005)89:5<652::aid-jps11>3.0.co;2-h
Cited by
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
A Comprehensive Review of mRNA Vaccines
Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457
PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00174 · Cited by 313
Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation
Su, K., Shi, L., Sheng, T., Yan, X., Lin, L., Meng, C., Wu, S., Chen, Y., Zhang, Y., Wang, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50093-7 · Cited by 264
Isaac, I., Patel, L., Tran, N., Singam, A., Yun, D., Guha, P., Park, S., & Bhattacharya, C. (2025) · Advanced Materials · doi:10.1002/adma.202507657 · Cited by 33
Metadata
- Authors
- Hald Albertsen, C., Kulkarni, J. A., Witzigmann, D., Lind, M., Petersson, K., & Simonsen, J. B.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 188
- Pages
- 114416
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W4283803576
- Cited by
- 1,185
- References
- 120
- FWCI
- 18.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.